DE69435136D1 - Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung - Google Patents

Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung

Info

Publication number
DE69435136D1
DE69435136D1 DE69435136T DE69435136T DE69435136D1 DE 69435136 D1 DE69435136 D1 DE 69435136D1 DE 69435136 T DE69435136 T DE 69435136T DE 69435136 T DE69435136 T DE 69435136T DE 69435136 D1 DE69435136 D1 DE 69435136D1
Authority
DE
Germany
Prior art keywords
alzheimer
disease
proteins
directed
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69435136T
Other languages
English (en)
Inventor
La Monte Suzanne M De
Jack R Wands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE69435136D1 publication Critical patent/DE69435136D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
DE69435136T 1993-04-20 1994-04-20 Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung Expired - Fee Related DE69435136D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5055993A 1993-04-20 1993-04-20

Publications (1)

Publication Number Publication Date
DE69435136D1 true DE69435136D1 (de) 2008-10-09

Family

ID=21965952

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435136T Expired - Fee Related DE69435136D1 (de) 1993-04-20 1994-04-20 Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung
DE69434844T Expired - Fee Related DE69434844T2 (de) 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69434844T Expired - Fee Related DE69434844T2 (de) 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung

Country Status (11)

Country Link
EP (2) EP0697893B1 (de)
JP (2) JP3513859B2 (de)
KR (1) KR100392244B1 (de)
AT (2) ATE312348T1 (de)
CA (1) CA2161097A1 (de)
DE (2) DE69435136D1 (de)
DK (2) DK0697893T3 (de)
ES (2) ES2312913T3 (de)
NZ (1) NZ266072A (de)
PT (1) PT1564293E (de)
WO (1) WO1994023756A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
KR19980702156A (ko) * 1995-12-12 1998-07-15 히라따 다다시 신규 dna, 신규 폴리펩티드 및 신규 항체
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
AU749348B2 (en) 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
WO1998039967A1 (en) 1997-03-12 1998-09-17 The General Hospital Corporation A method for treating or preventing alzheimer's disease
BR0209630A (pt) 2001-05-16 2004-03-30 Nymox Corp Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais
EP1541166B1 (de) * 2001-05-16 2007-12-19 Nymox Corporation Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen
US6770797B2 (en) 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
EP1714979A3 (de) * 2001-11-16 2007-04-25 Nymox Corporation Peptide für die Behandlung von Tumoren und anderen Zuständen, die das entfernen oder zerstören von Zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US8067378B2 (en) 2006-02-28 2011-11-29 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2023217890A1 (en) * 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006332C (en) * 1988-12-21 2003-04-08 Suzanne De La Monte Method of detecting neurological disease or dysfunction

Also Published As

Publication number Publication date
EP1564293B9 (de) 2009-08-19
CA2161097A1 (en) 1994-10-27
DK1564293T3 (da) 2009-01-12
ES2255054T3 (es) 2006-06-16
DK0697893T3 (da) 2006-02-20
EP1564293B1 (de) 2008-08-27
EP1564293A1 (de) 2005-08-17
EP0697893A1 (de) 1996-02-28
JPH08509808A (ja) 1996-10-15
WO1994023756A1 (en) 1994-10-27
ATE312348T1 (de) 2005-12-15
AU6666994A (en) 1994-11-08
AU674581B2 (en) 1997-01-02
PT1564293E (pt) 2008-12-02
DE69434844T2 (de) 2006-12-14
JP3513859B2 (ja) 2004-03-31
JP2004097227A (ja) 2004-04-02
KR100392244B1 (ko) 2003-11-28
NZ266072A (en) 1997-07-27
DE69434844D1 (de) 2006-10-19
ATE406444T1 (de) 2008-09-15
EP0697893A4 (de) 1996-12-18
ES2312913T3 (es) 2009-03-01
EP0697893B1 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
ATE406444T1 (de) Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung
EP0442961A4 (en) Hybrid procoagulant proteins
PT939804E (pt) Neutroquina alfa
SE8106641L (sv) Hybrida humanleukocytinterferoner
DE69735375D1 (de) Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
DE3786200D1 (de) Diagnostische verfahren zum nachweis von lymphomen bei menschen.
ATE231551T1 (de) Huntingtin-dna, protein und verwendung
DE3684295D1 (de) Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose.
ATE301716T1 (de) Vmp-ähnliche sequenzen von pathogener borrelia
ATE365744T1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69635207D1 (de) Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
NO177863C (no) Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
ATE187202T1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
NO962596L (no) Nytt tumorsupressorgen
ATE414772T1 (de) Das hohe knochenmasse gen auf 11q13.3
ATE312914T1 (de) Rdgb-proteine
Schröder et al. Identification of a novel platelet-derived neutrophil-chemotactic polypeptide with structural homology to platelet-factor 4
DE69033553T2 (de) Rekombinante herstellung von laktoperoxidase
EP0839910A3 (de) Spo-rel, ein relA/spoT Homolog aus Staphylococcus
MX9801603A (es) Alteraciones geneticas relacionadas con la enfermedad de alzheimer hereditaria.
EA199900339A1 (ru) Ген роста человека и область гена, ответственная за низкий рост
TH23725A (th) วัคซีนป้องกันโรคบิดสำหรับสัตว์ปีก

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee